Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strong Sobi With New Asset: A Takeover Target For Sanofi?

Executive Summary

Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?

You may also be interested in...



Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy

Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.  

Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion

Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.

Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk

Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel